Donanemab has already received a 'breakthrough therapy' designation from the FDA
No significant differences in language development seen at age 2 years for children born to mothers with epilepsy
ADHD medications may moderate the association between externalizing symptoms and risk for suicidality in children
Less than 5 percent of prescribers account for half of all buprenorphine treatment in the country
Patients report side effects, beliefs, and knowledge about bipolar disorder are top reasons for not taking medications
Women who initiated sleep medications rated their sleep disturbances similarly after one and two years
Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine versus sublingual buprenorphine
Symptoms are reduced in a majority of preschool-aged children who initiate therapy with α2-adrenergic agonists or stimulants for ADHD